tradingkey.logo

Novartis CEO: "It's Early Days" For Any Change In European Drug Pricing Due To MFN

ReutersFeb 4, 2026 7:05 AM

- Novartis AG NOVN.S:

  • NOVARTIS CEO SAYS US MOST-FAVORED-NATION REGULATION NOT HAVING A MATERIAL EFFECT ON OUR 2026 GUIDANCE

  • NOVARTIS CEO SAYS AGREEMENT ON US DRUG PRICES IS INCLUDED IN OUR MID-TERM GUIDANCE

  • NOVARTIS CEO SAYS "IT'S EARLY DAYS" FOR ANY CHANGE IN EUROPEAN DRUG PRICING IN THE CONTEXT OF MOST-FAVORED-NATION RULES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI